US Patent No: 7,655,228
Number of patents in Portfolio can not be more than 2000
Method of modulating the activity of functional immune molecules to GM2
Stats
-
Feb 2, 2010
Issued date -
Mar 15, 2007
filing date -
11/686,911
serial no -
In Force
status
Importance
Loading Importance Indicators...
Abstract
The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.
Loading the Abstract Image...
First Claim
Related Publications
Loading Related Publications...
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 5,830,470 Humanized antibodies to ganglioside GM.sub.2 | 40 | 1993 | |
| 6,018,032 Antibody against human interleukin-5-receptor .alpha. chain | 29 | 1997 | |
| 6,437,098 Human chimeric antibody specific for the ganglioside GD3 | 22 | 1999 | |
| 6,986,890 Anti-human VEGF receptor Flt-1 monoclonal antibody | 22 | 1999 | |
| 6,946,292 Cells producing antibody compositions with increased antibody dependent cytotoxic activity | 56 | 2001 | |
| 2003/0175,273 Human CDR-grafted antibody and antibody fragment thereof | 20 | 2002 | |
| 2004/0110,282 Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost | 30 | 2003 | |
| 2004/0132,140 Production process for antibody composition | 35 | 2003 | |
| 2005/0187,380 Method for treating Th2-mediated disease | 20 | 2005 | |
| 7,214,775 Method of modulating the activity of functional immune molecules | 50 | 2005 | |
| 2005/0272,916 Method of modulating the activity of functional immune molecules | 27 | 2005 | |
| 2006/0024,800 Method of modulating the activity of functional immune molecules | 24 | 2005 | |
| 2005/0216,958 Cells of which genome is modified | 21 | 2005 | |
| 2005/0262,593 Antibody composition-producing cell | 23 | 2005 | |
| 2006/0223,147 Process for producing glycoprotein composition | 22 | 2005 | |
| 2006/0063,254 Antibody composition-producing cell | 25 | 2005 | |
| 2006/0064,781 Antibody composition-producing cell | 28 | 2005 | |
| 2007/0010,009 Antibody Composition-Producing Cell | 19 | 2006 | |
| 2007/0166,300 Method of Modulating the Activity of Functional Immune Molecules | 20 | 2007 | |
| 2007/0166,301 Method of Modulating the Activity of Functional Immune Molecules | 20 | 2007 | |
| 2007/0166,302 Method of Modulating the Activity of Functional Immune Molecules | 20 | 2007 | |
| 2007/0166,303 Method of Modulating the Activity of Functional Immune Molecules | 20 | 2007 | |
| 2007/0166,304 Method of Modulating the Activity of Functional Immune Molecules | 20 | 2007 | |
| 2008/0261,301 Antibody Composition-Producing Cell | 19 | 2008 | |
|
|
|||
| 4,816,567 Recombinant immunoglobin preparations | 1314 | 1983 | |
| 6,169,070 Mer receptor activation by gas6 | 63 | 1996 | |
| 6,737,056 Polypeptide variants with altered effector function | 141 | 2000 | |
| 2003/0157,108 Glycoprotein compositions | 75 | 2002 | |
| 7,297,775 Polypeptide variants | 29 | 2002 | |
|
|
|||
| 2004/0093,621 Antibody composition which specifically binds to CD20 | 49 | 2002 | |
| 2004/0110,704 Cells of which genome is modified | 37 | 2003 | |
| 2005/0160,485 Mouse in which genome is modified | 20 | 2004 | |
| 2005/0226,867 IL-5R-specific antibody composition | 21 | 2004 | |
| 2005/0287,138 CCR4-specific antibody composition | 22 | 2004 | |
|
|
|||
| 6,602,684 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity | 78 | 1999 | |
| 2004/0072,290 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity | 44 | 2003 | |
| 2005/0074,843 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity | 32 | 2003 | |
| 2007/0111,281 Antigen binding molecules having modified Fc regions and altered binding to Fc receptors | 26 | 2006 | |
|
|
|||
| 5,880,268 Modulators of the interaction between ICAM-R and .alpha..sub.d /CD18 | 27 | 1995 | |
| 5,932,703 Macrophage derived chemokine and chemokine analogs | 32 | 1996 | |
| 6,498,015 Methods of identifying agents that modulate the binding between MDC and an MDC receptor | 27 | 1997 | |
|
|
|||
| 6,488,930 Anti-CCR4 antibodies and methods of use therefor | 27 | 1999 | |
| 7,138,117 Anti-CCR4 antibodies and methods of use therefor | 20 | 2002 | |
|
|
|||
| 6,054,304 .alpha.1-6 fucosyltransferase | 39 | 1998 | |
| 6,291,219 .alpha.1-6 fucosyltransferase | 20 | 1999 | |
|
|
|||
| 2004/0002,077 siRNA expression system and method for producing functional gene knock-down cell using the system | 44 | 2002 | |
| 2005/0048,647 Sirna expression system and process for producing functional gene knockdown cell or the like using the same | 31 | 2004 | |
|
|
|||
| 5,977,316 Monoclonal antibody 1A7 and related polypeptides | 28 | 1996 | |
| 5,935,821 Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma | 35 | 1996 | |
|
|
|||
| 7,502,497 Method and system for extracting an area of interest from within an image of a biological surface | 19 | 2007 | |
|
|
|||
| 7,033,589 γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics | 22 | 1999 | |
|
|
|||
| 5,272,070 Method for the preparation of cell lines producing Man.sub.3 GlcN.sub.ac 2 asparagine-linked gylcans and cell lines produced thereby | 54 | 1991 | |
|
|
|||
| 5,453,363 Process for the activation of t-PA or Ing after genetic expression in prokaryotes | 33 | 1994 | |
|
|
|||
| 4,350,683 Antibody production from hybrid cell line | 60 | 1980 | |
|
|
|||
| 5,891,996 Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use | 62 | 1995 | |
|
|
|||
| 2003/0190,316 Stabilized antibody-containing preparations | 38 | 2003 | |
|
|
|||
| 5,658,789 Promotion of epithelial cell adhesion and hemidesmosome assembly by a laminin-like molecule | 26 | 1995 | |
|
|
|||
| 6,762,174 Low molecular weight compounds administered together with anti-cancer agents to prevent or treat cancer and pharmaceutical compositions thereof | 18 | 1999 | |
|
|
|||
| 6,189,781 Terminal unit having function for converting commodity information into bar code and vice versa | 30 | 1994 | |
|
|
|||
| 5,728,568 Human GDP-mannose 4,6 dehydratase | 28 | 1996 | |
|
|
|||
| 6,150,132 Chemokine receptor able to bind to MCP-1, MIP-1.alpha. and/or RANTES. Its uses | 38 | 1997 | |
|
|
|||
| 4,757,018 Myeloma cell lines and uses thereof | 26 | 1985 | |
|
|
|||
| 6,455,043 Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody | 49 | 1999 | |
|
|
|||
| 6,245,332 Modulation of systemic memory T cell trafficking | 28 | 1999 | |
|
|
|||
| 5,672,502 Animal cell culture | 28 | 1995 | |
|
|
|||
| 5,922,845 Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor antibodies | 64 | 1996 | |
|
|
|||
| 2003/0170,813 Process for producing glycoprotein | 21 | 2003 | |
|
|
|||
| 2007/0166,305 Method of Modulating the Activity of Functional Immune Molecules | 20 | 2007 | |
|
|
|||
| 6,129,913 Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders | 24 | 1997 | |
|
|
|||
| 5,665,569 HIV immunotherapeutics | 32 | 1994 | |
|
|
|||
| 5,614,385 Methods and compositions for high protein production from recombinant DNA | 28 | 1995 | |
|
|
|||
| 5,858,983 Inhibition of cell adhesion protein-carbohydrate interactions | 34 | 1995 | |
|
|
|||
| 6,238,894 .alpha.1,2 fucosyltransferase | 24 | 1999 | |
|
|
|||
| 4,721,777 Process for the virus-inactivation of immunoglobulin | 34 | 1985 | |
|
|
|||
| 6,350,868 Antisense human fucosyltransferase sequences and methods of use thereof | 22 | 2000 | |
|
|
|||
| 5,464,764 Positive-negative selection methods and vectors | 189 | 1993 | |
|
|
|||
| 4,849,509 Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies | 47 | 1987 | |
Patent Citation Ranking
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 3.5 Year Payment | $1600.00 | $800.00 | $400.00 | Aug 2, 2013 |
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Aug 2, 2017 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Aug 2, 2021 |
| Fee | Large entity fee | small entity fee | micro entity fee |
|---|---|---|---|
| Surcharge - 3.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge - 7.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
| Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |